Search News
| 106.88 Delayed Data As of Sep 18 |  +1.17 / +1.11%Today’s Change | 73.69 Today|||52-Week Range 107.84 | +26.55% Year-to-Date |
| Previous close | 105.71 |
| Today’s open | 105.87 |
| Day’s range | 105.11 - 107.19 |
| Volume | 3,668,807 |
| Average volume (3 months) | 3,594,402 |
| Market cap | $113.5B |
| Earnings growth (last year) | -107.36% |
| Earnings growth (this year) | +27.79% |
| Earnings growth (next 5 years) | +14.10% |
| Revenue growth (last year) | +7.77% |
| P/E ratio | NM |
| Price/Sales | 3.88 |
| Price/Book | 10.03 |
| Today’s change | Today’s % change | |
|---|---|---|
| SNYSanofi | +0.21 | +0.48% |
| ABTAbbott Laboratories | +0.74 | +1.09% |
| BMYBristol-Myers Squibb | +0.18 | +0.29% |
| GSKGlaxoSmithKline | +0.42 | +1.07% |
| Next reporting date | October 23, 2018 |
| EPS forecast (this quarter) | $1.35 |
| Annual revenue (last year) | $22.9B |
| Annual profit (last year) | -$204.1M |
| Net profit margin | -0.89% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer David A. Ricks |
Senior VP-Biotechnology & Autoimmunity Research Thomas F. Bumol |
Corporate headquarters Indianapolis, Indiana |
